Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P, Vignetti M, Vitale A, Mancini M, Cimino G, Palmieri S, Di Raimondo F, Specchia G, Fabbiano F, Cantore N, Mosna F, Camera A, Luppi M, Annino L, Miraglia E, Fioritoni G, Ronco F, Meloni G, Mandelli F, Andreeff M , Milella M, Fo R, Tafuri A, Working Party GAL
10.1016/j.redox.2023.102684 231 WangX.YuanP.ZengM.SunM.ZhengX.et al (2023c)
doi: 10.3390/antiox12051075 84 ScharpingNEMenkAVMoreciRSWhetstoneRDDadeyREWatkinsSCet al
If your doctor can justify the medical necessity of IV therapy, you have a better chance of getting coverage under a PPO plan
2) The study performed by the research team of Mass et al investigated the effects of AcSDKP on hematologic toxicity and bone marrow recovery following doxorubicin (DOX) treatment in BALB/c mice